NCT01930786 (ASPIRE) is a clinical trial of onabotulinumtoxinA in Muscle Spasticity, sponsored by Allergan.

Who is sponsoring NCT01930786?

NCT01930786 is sponsored by Allergan.

What drugs are being tested in NCT01930786?

Interventions in NCT01930786: onabotulinumtoxinA.

What condition does NCT01930786 study?

NCT01930786 studies Muscle Spasticity.

Is NCT01930786 still recruiting?

NCT01930786 is currently completed. Last updated 11 February 2019.

Last reviewed 2019-02-11 · How we verify

NCT01930786: ASPIRE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Adult Spasticity Registry of OnabotulinumtoxinA Treatment

Completed Last updated 11 February 2019

What this trial tests

trial testing onabotulinumtoxinA in Muscle Spasticity in 744 participants. Completed in 9 October 2017.

Timeline

16 October 2013

Primary endpoint
9 October 2017

9 October 2017

Quick facts

Lead sponsor	Allergan
Status	Completed
Study type	OBSERVATIONAL
Enrollment	744
Start date	16 October 2013
Primary completion	9 October 2017
Estimated completion	9 October 2017
Sites	55 locations across France, Italy, Taiwan, United Kingdom, Germany, United States, Spain

Drugs / interventions tested

onabotulinumtoxinA (ONABOTULINUMTOXINA) — full drug profile →

Conditions studied

Muscle Spasticity — all drugs for Muscle Spasticity →

Sponsor

Allergan — full company profile →

Who can join

18 and older, any sex, with Muscle Spasticity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a registry study in adults with spasticity to determine onabotulinumtoxinA use in clinical practice. Treatment will be administered in accordance with physician standard practice. All treatment decisions lie with the physician.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Individualized OnabotulinumtoxinA Treatment for Upper Limb Spasticity Resulted in High Clinician- and Patient-Reported Satisfaction: Long-Term Observational Results from the ASPIRE Study.
Francisco GE, Jost WH, Bavikatte G, Bandari DS, et al · · 2020 · cited 22× · PMID 31953896 · DOI 10.1002/pmrj.12328
Long-Term Observational Results from the ASPIRE Study: OnabotulinumtoxinA Treatment for Adult Lower Limb Spasticity.
Esquenazi A, Bavikatte G, Bandari DS, Jost WH, et al · · 2021 · cited 11× · PMID 33151636 · DOI 10.1002/pmrj.12517
Real-World Adherence to OnabotulinumtoxinA Treatment for Spasticity: Insights From the ASPIRE Study.
Esquenazi A, Francisco GE, Feng W, Baricich A, et al · · 2021 · cited 7× · PMID 34245684 · DOI 10.1016/j.apmr.2021.06.008
High clinician- and patient-reported satisfaction with individualized onabotulinumtoxinA treatment for spasticity across several etiologies from the ASPIRE study.
Francisco GE, Bandari DS, Bavikatte G, Jost WH, et al · · 2020 · cited 6× · PMID 32875289 · DOI 10.1016/j.toxcx.2020.100040
Pain, disability, and quality of life in participants after concurrent onabotulinumtoxinA treatment of upper and lower limb spasticity: Observational results from the ASPIRE study.
Bavikatte G, Francisco GE, Jost WH, Baricich A, et al · · 2024 · cited 4× · PMID 38813838 · DOI 10.1002/pmrj.13195
Safety and Real-World Dosing of OnabotulinumtoxinA for the Treatment of Adult Spasticity: Post Hoc Analysis of the Adult Spasticity International Registry Study.
Bavikatte G, Esquenazi A, Dimyan MA, Dashtipour K, et al · · 2024 · cited 4× · PMID 38206635 · DOI 10.1097/phm.0000000000002410
Relief of pain associated with spasticity in adult patients after treatment with onabotulinumtoxinA: Post hoc observational results from the ASPIRE study.
Wissel J, List C, Schwartz M, Nelson M, et al · · 2026 · PMID 41025675 · DOI 10.1002/pmrj.70013

Verify or expand the search:

Other trials of onabotulinumtoxinA

Trials testing the same drug.

NCT03827122 — Botulinum Toxin A Injectable Solution in the Management of Bruxism: A Clinical Trial Study · Phase 2 · unknown
NCT03373162 — Functional Effects of Botox on the Brain Using MRS and fMRI · Phase 4 · completed
NCT03043287 — Voiding Efficiency, a Predictor of Clean Intermittent Catheterization (CIC) · completed
NCT03052764 — Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder i · Phase 4 · completed
NCT02191579 — Efficacy and Safety Study of BOTOX® Compared to Topiramate for the Prevention of Chronic Migraine in Adults · Phase 4 · completed

Other recruiting trials for Muscle Spasticity

Currently open trials in the same condition.

NCT07118228 — Ultrasonographic Assessment of Muscle Morphology, Function, and Clinical Findings in Spastic Cerebral Palsy · recruiting
NCT06674785 — SIRS-ESWT Trial: Shoulder Internal Rotator Spasticity Trial Treated With Extracorporeal Shock Wave Therapy Trial · NA · recruiting
NCT06902168 — Effect of Diving and Aquatic Exercises on Muscle Spasticity and Motor Function in Children With Spastic Cerebral Palsy · NA · recruiting
NCT06733025 — Comparing Upper Limb Surgery and Botulinum Toxin for Spasticity: A Paired Design Study · NA · recruiting
NCT06536751 — Therapeutic Photobiomodulation and Tretament of Spasticity · Phase 2, PHASE3 · recruiting

Other Allergan trials

Trials by the same sponsor.

NCT04609020 — Study to Evaluate Subject Satisfaction With Facial Appearance and Impact of Combined Facial Treatment · Phase 4 · completed
NCT05452070 — A Study to Assess Adverse Events and Change in Disease Activity of HArmonyCa Lidocaine Injectable Gel for Mid Face Soft · Phase 3 · completed
NCT05393089 — Study of AGN-190584 Eye Drops to Assess Safety and Efficacy in Participants Aged 40-80 Years With Pseudophakic Presbyopi · Phase 2 · withdrawn
NCT05152576 — A Study To Assess the Adverse Effects and Change in Condition of OnabotulinumtoxinA X Injection in Adult Participants Wi · Phase 2 · completed
NCT05088980 — Study to Assess Effectiveness and Adverse Events of JUVEDERM VOLBELLA With Lidocaine Injection in Correcting Infraorbita · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01930786 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Allergan
Last refreshed: 11 February 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01930786.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing